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Abstract: Age-related macular degeneration (AMD) is an ocular disease that causes damage 
to the retinal macula, mostly in the elderly. Normal aging processes can lead to structural and 
blood ﬂ  ow changes that can predispose patients to AMD, although advanced age does not 
inevitably cause AMD. In this review, we describe changes that occur in the macular structure, 
such as the retinal pigment epithelium and Bruch’s membrane, with advancing age and in AMD. 
The role of genetics in AMD and age-related changes in ocular blood ﬂ  ow that may play a role 
in the pathogenesis of AMD are also discussed. Understanding the pathophysiology of AMD 
development can help guide future research to further comprehend this disease and to develop 
better treatments to prevent its irreversible central vision loss in the elderly.
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Introduction
Age-related macular degeneration (AMD) is an ocular disease that involves the 
posterior aspect of the retina called the macula. The macula facilitates central vision 
and permits high-resolution visual acuity due to its dense concentration of cone 
photoreceptors (Fine et al 2000). There is an early and late stage of AMD. In the early 
stage, there is formation of large drusen and pigmentary abnormalities (Fine et al 
2000). The late stage is divided into two groups: nonexudative or “dry” form and 
an exudative/neovascular or “wet” form. The nonexudative form is characterized by 
atrophic changes in the macula and clinically, has a slower deterioration and better 
preservation of visual acuity than exudative AMD (Fine et al 2000). Exudative AMD 
involves choroidal neovascularization, which is the formation of new abnormal blood 
vessels in the choriocapillaries through Bruch’s membrane (Figure 1). These vessels 
have a greater tendency of leakage and bleeding into the macula, ultimately leading to 
irreversible damage to the photoreceptors if left untreated (Fine et al 2000). Hence, 
the exudative form accounts for most cases of signiﬁ  cant visual loss from AMD 
(Ciulla et al 2001).
AMD is the leading cause of visual deterioration and legal blindness in patients 
over 60 years of age (Klein et al 1997). The loss of central vision and high-resolu-
tion visual acuity from untreated AMD can lead to an irreversible loss of reading, 
facial recognition, and driving (Fine et al 2000). Changes in the macula occur over 
time and occur more often in the elderly. The prevalence of AMD among 40- to 
49-year-olds is 2.1%, which increases dramatically to 35% among those over 80 years 
of age (National Eye Institute 2007). Additionally, the disease can progress with 
approximately 10%–20% of patients with nonexudative AMD progressing to the 
exudative form if untreated (Hyman and Neborsky 2002). Furthermore, almost 40% 
of patients have bilateral disease (Topouzis et al 2006). The risk factors for AMD 
include ethnicity, gender, hypertension, genetics, diet, and sunlight exposure. Studies Clinical Interventions in Aging 2008:3(3) 474
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have shown that the late stages of AMD are more common 
in whites than in other ethnic groups and that women are 
affected more than men (Hyman and Neborsky 2002). 
Nevertheless, the strongest, most consistent risk factors are 
smoking and age (Hyman and Neborsky 2002).
Although aging will not inevitably lead to AMD 
development, there are changes with age that can predis-
pose the eye to development of AMD. Primary senescence 
of retinal pigment epithelial cells and Bruch’s membrane 
can lead to accumulation of metabolic debris and drusen. 
Furthermore, primary abnormalities in ocular perfusion 
worsen with age, secondarily causing dysfunction of the 
retinal pigment epithelial cells, predisposing eyes to AMD. 
These anatomical changes together with an individual’s 
genetic make-up and environmental risk factors set the stage 
for the development of AMD (Ciulla et al 2001).
In this report, we focus on the role that aging plays in the 
pathogenesis of AMD. We start from a structural approach 
with alterations in the retinal pigment epithelium-Bruch’s 
membrane-choriocapillaris complex. Then we focus on 
the vascular changes with an attention to ocular blood 
ﬂ  ow alterations that correlate with AMD lesion development. 
Finally, we discuss the role of genetics in development of 
AMD.
Structural changes with age 
and in AMD
The outer retina is made up of the retinal pigment epithelium 
and photoreceptors. The retinal pigment epithelial cells form the 
outer blood-retinal barrier to facilitate selective transport between 
the choroidal blood vessels and the outer retina (Salvi et al 2006). 
Therefore, they play a major role in rod and cone photoreceptor 
integrity. The retinal pigment epithelium is a phagocytic system 
that is essential to the renewal of photoreceptors (de Jong 2006). 
When the tips (or outer segments) of photoreceptors are shed, 
retinal pigment epithelial cells have been shown to engulf and 
to degrade its components (de Jong 2006). Burns and Feeney-
Burns (1980) speculate that the retinal pigment epithelium then 
transports the engulfed cytoplasmic material through Bruch’s 
membrane into the choriocapillaries.
Age-related processes that occur in the retinal pigment 
epithelium-Bruch’s membrane-choriocapillaris complex 
Figure 1 An illustration of the late form of AMD, showing the growth of the choroidal neovascularization from the choroicapillaris through the Bruch’s membrane into the 
subretinal space. These new vessels are abnormal and have a higher tendency of leakage and bleeding. Reprinted with permission from Bressler NM, Bressler SB, Fine SL 1988. 
Age-related macular degeneration. Surv Ophthalmol, 32:375–413. © 1998 Elsevier.Clinical Interventions in Aging 2008:3(3) 475
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can precede the development of AMD (Liang and Godley 
2003). With advancing age, retinal pigment epithelial cells 
undergo an increase in pleomorphism, a decrease in the 
concentration of cells in the posterior pole, and decreased 
melanin content (Salvi et al 2006). Senescent retinal pigment 
epithelial cells accumulate metabolic debris from remnants 
of incomplete degradation of phagocytized rod and cone 
membranes (Ciulla et al 2001). Fatty acids from the outer 
segment receptors are degraded by lipid peroxidation, a 
process that increases with age in the macula (Zarbin 2004). 
Susuki et al (2007) found oxidized phospholipids present 
in photoreceptors and retinal pigment epithelial cells in 
the macula of the normal eyes, with increased quantities 
with advanced age. Metabolic debris includes lipofuscin, 
an undegradable byproduct of outer segment photoreceptor 
metabolism, which increases in concentration within retinal 
pigment epithelial cell cytoplasm over time (Feeney-Burns 
et al 1984). It is believed that lipofuscin and fatty acids are 
continuously exposed to light and high oxygen tension, which 
initiates the production of reactive oxygen species (Zarbin 
2004). It is further postulated that these cause oxidative 
damage to the cellular mitochondria and to mitochondrial 
DNA, which is most susceptible to this oxidative stress 
(Liang and Godley 2003). Injury to the mitochondria leads 
to a reduction in energy production, compromises cellular 
and physiologic functioning, and can subsequently signal 
apoptosis in retinal pigment epithelial cells (Liang and 
Godley 2003; Zarbin 2004). Increased apoptosis eventually 
causes a decreased number of retinal pigment epithelial cells 
(Cai et al 1999). In order to counteract the formation of reac-
tive oxygen species, retinal pigment epithelial cells contain 
anti-oxidants, which decrease with age (Liang and Godley 
2003). The Age-Related Eye Disease Study (AREDS) has 
demonstrated that the administration of anti-oxidants, such 
as vitamins B, C, E, and zinc, signiﬁ  cantly slows the rate of 
progression from high-risk nonexudative AMD to exudative 
AMD (AREDS 2001).
Retinal pigment epithelial cell damage also leads to the 
production of an abnormal extracellular matrix, which alters 
retinal pigment epithelium function, and causes choriocapil-
lary loss associated with geographic atrophy (Zarbin 2004). 
Damaged retinal pigment epithelial cells can promote an 
inﬂ  ammatory response that has been implicated in the devel-
opment of AMD and the development of neovascularization 
(Moshfeghi and Blumenkranz 2007). Once damaged, these 
retinal pigment epithelial cells can secrete growth factors, 
such as vascular endothelial growth factor (VEGF), basic 
ﬁ  broblast growth factor (bFGF), and transforming growth 
factor beta (TGF-ß). These cytokines play a major role in the 
formation of choroidal neovascularization in AMD (Lutty 
et al 1999). Recent evidence suggests that within the eye, 
there is a ﬁ  ne balance between endogenous angiogenic and 
anti-angiogenic growth factors. Imbalances between these 
factors can lead to choroidal neovascularization (Bhutto et al 
2006). VEGF has been found to be one of the key angiogenic 
growth factors. The family of VEGF proteins, including 
VEGF-A, VEGF-B, VEGF-C, VEGF-D, and PlGF, exert 
their function through tyrosine kinase receptors (Andreoli 
and Miller 2007). VEGF has been shown to be present in 
choroidal neovascularization membranes (Otani et al 2002). 
Conversely, pigment epithelium derived factor (PEDF) is a 
potent endogenous anti-angiogenic growth factor. PEDF has 
been shown to signiﬁ  cantly suppress VEGF-induced prolif-
eration and migration of vascular endothelial cells (Bhutto 
et al 2006). Decreased PEDF levels have been reported in the 
vitreous samples of exudative AMD patients (Holekamp et al 
2002). Choroidal PEDF immunoreactivity is also reduced in 
AMD patients compared to age-matched controls (Bhutto 
et al 2006). Currently, medications targeting VEGF, such as 
bevacizumab and ranibizumab, are widely used in the treat-
ment of neovascular AMD. Future therapies may involve 
anti-angiogenic growth factors, such as PEDF.
Various other proteins can also inﬂ  uence the pathogenesis 
of AMD. One such molecule, ubiquitin, is an intracellular 
protein that regulates numerous cellular processes, such as 
cell-cycle progression, signal transduction, transcriptional 
regulation, and endocytosis (Hershko and Ciechanover 1998). 
It has been implicated in immune responses and apoptosis 
(Hershko and Ciechanover 1998). Ubiquitin is prominent in 
ganglion cells, retinal pigment epithelium and age-related 
subretinal pigment epithelium deposits (Shang and Taylor 
2004). The ubiquitin pathway involves two steps. The ﬁ  rst 
phase is ubiquitination whereby a substance that needs to 
be degraded is tagged with speciﬁ  c amino acid sequences. 
Subsequently, tagged molecules undergo proteolytic degra-
dation through ubiquitin processing enzymes. This process 
allows damaged or obsolete proteins to be degraded before 
they aggregate within the cytoplasm. Over time, this pro-
tective pathway becomes compromised (Shang and Taylor 
2004). Additionally, hydrogen peroxide (H2O2) increases 
the level of oxidized glutathione, which further interferes 
with ubiquitination (Shang and Taylor 2004). Ubiquitin,
without the active ubiquitin processing enzymes, is found 
in subretinal pigment epithelial deposits (Shang and Taylor 
2004). It is speculated that with age, ubiquitinated proteins in 
retinal pigment epithelial cells do not undergo degradation by Clinical Interventions in Aging 2008:3(3) 476
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the ubiquitin processing enzymes (Shang and Taylor 2004). 
Therefore, changes in the ubiquitin pathway compromise 
protein degradation and contribute to subretinal pigment 
epithelial protein accumulation, which occurs in both 
advanced age and AMD.
Drusen are subretinal pigment epithelium deposits that 
are the clinical hallmark of AMD (Sivaprasad et al 2005). 
There are two classiﬁ  cations of drusen, depending on where 
they are located: basal linear and basal laminar deposits. 
Basal linear deposits accumulate between the basal lamina 
of the retinal pigment epithelium and the inner collagenous 
zone of Bruch’s membrane (Sivaprasad et al 2005). Basal 
laminar deposits are found between the basement membrane 
and plasma membrane of the retinal pigment epithelium and 
consist of basement membrane proteins and collagen. The 
thickness of drusen deposits have been shown to correlate 
with the degree of retinal pigment epithelium degeneration, 
photoreceptor fallout, and vision loss (Sarks et al 2007). 
Drusen size, number, and degree of conﬂ  uence are signiﬁ  -
cant risk factors for the development of AMD (Bressler et al 
1990). Soft and conﬂ  uent drusen are a classic clinical hall-
mark of AMD. Interestingly, the molecular composition of 
drusen and the atherosclerotic deposits within blood vessels 
share many similarities (Sivaprasad et al 2005). Both con-
tain vitronectin (a multifunctional plasma and extracellular 
matrix protein), apolipoprotein E, complement components 
and lipids (Mullins et al 2000). Nevertheless, a proteonomic 
analysis comparing drusen in AMD patients and age-matched 
controls found that although two-thirds of the proteins were 
similar between the two groups, one-third of the proteins 
detected in drusen from AMD patients were not found in 
controls (Crabb et al 2002). Furthermore, it is postulated 
that the development of drusen is most likely a selective 
and active process than a passive accumulation of proteins 
and lipids (Crabb et al 2002). Therefore, drusen formation 
may be inﬂ  uenced by an individual’s genetic predisposition 
or environmental stressors, which helps explain why all aged 
patients do not develop AMD (Figure 2).
With age, drusen can further accumulate on either side 
of the elastin layer in Bruch’s membrane (Feeney-Burns and 
Ellersieck 1985). Bruch’s membrane is a connective tissue 
layer that lies between the metabolically active retinal pigment 
epithelial cells and the choriocapillaris. It supplies nutrition 
to retinal pigment epithelial cells (Sivaprasad et al 2005) and 
regulates ionic and metabolic exchange between the retinal 
pigment epithelium and choriocapillaries (Ramrattan et al 
1994). With age, Bruch’s membrane increases in thickness 
from 2 μm in the ﬁ  rst decade of life to 4.7 μm in the 10th 
decade (Ramrattan et al 1994). Thickened Bruch’s membrane 
can predispose itself to crack formation (Ciulla et al 2001). 
In patients with exudative AMD, Bruch’s membrane is more 
calciﬁ  ed and fragmented than in age-matched controls or 
patients with nonexudative AMD. These cracks can facilitate 
the development of choroidal neovascular membranes thus 
transforming nonexudative to exudative AMD (Spraul and 
Grossniklaus 1997).
The increased thickness of Bruch’s membrane involves 
both the elastin and collagenous layers and results from 
decreased degradation and increased production of the 
extracellular matrix (Zarbin 2004). Matrix mellatoproteinases 
(MMPs), which play a role in the degradation of extracellular 
matrix, and the tissue inhibitors of metalloproteinase 
(TIMPs), which regulate the activity of MMPs, have been 
found to change with age (Zarbin 2004). Increased content 
of the inactive form of MMP-2, MMP-9 as well as TIMP-3 
have been found in the Bruch’s membrane of aged patients 
(Zarbin 2004). Additionally, MMPs can facilitate choroidal 
neovascularization. Activated by VEGF, MMPs break down 
the extracellular matrix, allowing the growth of new vessels 
(Steen et al 1998). MMP-2 and MMP-9 have been localized 
to areas of new vessel development and to the enveloping 
Bruch’s-like membrane suggesting that these enzymes 
may be cooperatively involved in the progressive growth 
of choroidal neovascular membranes in AMD. Neverthe-
less, the amounts of noncollagen proteins, lipid deposits, 
heparin sulfate, laminin, and ﬁ  bronectin are also increased 
in Bruch’s membrane with age (Zarbin 2004). Additionally, 
glycosaminoglycans increase in size and advanced glycation 
end products accumulate within Bruch’s membrane over 
time (Zarbin 2004). The accumulation of cholesterol esters 
in Bruch’s membrane with advancing age is similar to that 
observed in the arterial intima in atherosclerosis (Curcio 
et al 2001). This increase in lipid content creates a hydro-
phobic environment, which changes the ﬂ  ux of solutes and 
ﬂ  uids across Bruch’s membrane (Bird and Marshall 1986). 
Therefore, changes in thickness, molecular composition and 
electric charge leads to an age-related loss of permeability 
in Bruch’s membrane and alters the movement of nutritional 
factors from the choriocapillaries toward the retinal pigment 
epithelial layer and subretinal space, thereby affecting the 
available nutrients for the outer retina (Zarbin 2004).
Ocular blood ﬂ  ow changes with age
There is a progressive decrease in the thickness of the 
choroid from 193 μm in the ﬁ  rst decade of life to 84 μm 
in the 10th decade (Ramrattan et al 1994). There is also a Clinical Interventions in Aging 2008:3(3) 477
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45% decrease in choriocapillary density and a 34% decrease 
in the lumen diameter of the choriocapillaries with advancing 
age (Ramrattan et al 1994). Reduced numbers of macular 
arterioles and decreased intensity of dye in the macular 
region have been demonstrated over time using indocyanine 
green angiography (Nishiyama et al 2001). These age-related 
changes were noted only in the arteries, but not in veins. Fur-
thermore, choroidal blood ﬂ  ow changes have been reported 
with advancing age (Ramrattan et al 1994). Pulsatile ocular 
blood ﬂ  ow reﬂ  ects the total pulsatile component of ocular 
blood ﬂ  ow and since most of the ocular blood volume is 
present in the choroid, it mainly represents the choroidal 
circulation (Sandhu et al 2007). Ravalico et al (1996) and 
Lam et al (2003) both found a decline in the pulsatile ocular 
blood ﬂ  ow with age. Animal models have shown a 35%–42% 
reduction in ocular blood ﬂ  ow and a 57%–93% increase in 
ocular vascular resistance in aged rats compared with juvenile 
or adult rats (Salter et al 1998). Age-related changes in the 
reﬂ  exive choroidal vasodilatation following hypoperfusion 
have also been shown in rat models (Fitzgerald et al 2005). 
Neurogenic choroidal blood ﬂ  ow control declines with age 
both in human and in animal studies (Fitzgerald et al 2005). 
With the use of laser Doppler ﬂ  owmetry, Grunwald et al 
(1998) reported age-related decreases in choroidal blood 
ﬂ  ow in the fovea, which was related to decreases in blood 
volume but not velocity.
The use of color Doppler imaging provides measure-
ments of the retrobulbar vasculature, namely the ophthalmic, 
central retinal and short posterior ciliary arteries. Retro-
bulbar changes have been demonstrated with advancing 
age. Age-related decreases in peak systolic velocity and 
end-diastolic velocity of the ophthalmic artery have been 
reported (Harris et al 2000; Lam et al 2003). Additionally, 
Pourcelot’s resistive index was increased in the ophthalmic 
artery (Harris et al 2000, Lam et al 2003). Groh et al (1996) 
found a decrease in central retinal artery blood ﬂ  ow by 
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Decrease in choriocapillary
density
Decreased lumen diameter of
choriocapillaries
Increased resistance to flow
Reduced choroidal flow
Reduced choroidal perfusion
Senescence of RPE cells
Accumulation of waste products and
formation of drusen
Thickening of Bruch’s membrane
Change in the composition of Bruch’s
membrane
Changes in the extracellular matrix
Increase in oxidative stress
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Environmental Risk Factors
AMD
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Figure 2 The vascular and nonvascular theory of AMD. The vascular theory, suggested by Friedman (1997), states that with increased resistance in the choroidal vessels, there 
is an increase in the osmotic gradient against which the retinal pigment epithelial cells must pump. This leads to retinal pigment epithelial cell dysfunction and the accumula-
tion of metabolic debris and drusen formation. Furthermore, the decrease in choroidal perfusion causes ischemic/hypoxic injury and increased oxidative stress, which can 
signal choroidal neovascularization formation. On the other hand, in the nonvascular theory, senescent retinal pigment epithelial cells can lead to retinal pigment epithelial cell 
dysfunction, which in turn can cause choriocapillary atrophy. Over time, and individual’s genetic predisposition and environmental stressors in the setting of structural and 
vascular changes make the eye more susceptible to AMD development.Clinical Interventions in Aging 2008:3(3) 478
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approximately 6%–11% per decade with an increase in the 
resistive index. On the other hand, Harris et al (2000) found 
that central retinal artery ﬂ  ow velocity was unaffected by age in 
both sexes. Nevertheless, they did ﬁ  nd that end-diastolic veloc-
ity of the posterior ciliary arteries decreased and the resistive 
index increased with age in women, but not in men.
The perfusion of the optic nerve head is also altered 
with increasing age. Boehm et al (2005) used laser Doppler 
ﬂ  owmetry to ﬁ  nd that volume and ﬂ  ow in the optic nerve 
decreased with age, suggesting that blood supply is reduced 
in elderly subjects. Neuroretinal rim and lamina cribrosa 
blood ﬂ  ow also decreases with advancing age (Embelton 
et al 2002). Additionally, Rizzo et al (1991) used a laser 
Doppler technique to demonstrate that advancing age is 
associated with a reduction in capillary red blood cell speed 
at the optic nerve head.
Ocular blood ﬂ  ow changes in AMD
Atherosclerosis has been postulated to be associated with late 
stages of AMD through its effect on the choroidal circulation 
and possible deposition of lipids in the Bruch’s membrane 
(Freidman 2000; Curcio et al 2001). A history of cardiovas-
cular disease and increased levels of cholesterol and stage 2 
hypertension are strongly associated with neovascular AMD 
(Hogg et al 2008). The Rotterdam Eye Study demonstrated 
that persons with subclinical cardiovascular disease, as mani-
fested by carotid artery plaques, were nearly ﬁ  ve times more 
likely to have late AMD compared to patients without such 
plaques (Vingerling et al 1995a). The Multiethnic Study of 
Atherosclerosis (MESA) found an association between the 
severity of the intima-media thickness of the carotid artery 
and early AMD in black participants (Klein et al 2007a). 
Nevertheless, they did not find an association between 
severity of subclinical atherosclerosis and early AMD in 
the entire MESA cohort (Klein et al 2007a). The Women’s 
Health Initiative Sight Exam Ancillary Study (WHISE) 
further reported a positive association between elevated sys-
tolic blood pressure and the presence of soft drusen, which 
correlated inversely with retinal pigment epithelial depig-
mentation and exudative AMD (Klein et al 2007b). Diastolic 
blood pressures and mean arterial blood pressures positively 
correlated with an increased risk of early AMD even after 
controlling for age (Klein et al 2007b). Although the rela-
tionship between blood pressure and AMD is not always 
consistent, several studies have demonstrated an association. 
In the Beaver Dam Eye Study, persons with hypertension at 
baseline were approximately two to three times more likely 
to develop neovascular macular degeneration after 10 years 
of follow-up than age-matched controls (Klein et al 2003). 
Furthermore, the Age-Related Macular Degeneration Risk 
Factor Study reported hypertension and high cholesterol 
to be associated with increased risk of neovascular AMD 
(Hyman et al 2000).
Since the choriocapillaris supplies the retinal pigment 
epithelial cells and the outer retina, a primary perfusion defect 
in the choriocapillaries could lead to loss or dysfunction of 
retinal pigment epithelial cells (Ciulla et al 2001). Spraul 
et al (1996) found increased total luminal area of peripheral 
choroidal vessels and decreased density of choroidal vessels 
in the macular area of eyes with AMD. In his theory on the 
development of AMD, Friedman (1997) hypothesized that 
with age, lipoid inﬁ  ltration occurs within the sclera, Bruch’s 
membrane and the wall of blood vessels, which leads to a 
decrease in the scleral and choroidal vessels compliance. 
This decrease in compliance can increase the resistance of 
the choroidal blood vessels and decrease choroidal perfusion 
(Friedman 1997). The elevated resistance can also increase 
intravascular pressure and raise hydrostatic pressure. Fur-
thermore, scleral rigidity has been shown to increase with 
age (Lam et al 2003; Pallikaris et al 2005) and in patients 
with AMD (Friedman et al 1989). All of these changes in the 
choriocapillaris can impair the retinal pigment epithelial cell 
transport, promote increased debris accumulation and cause 
dysfunction of the retinal pigment epithelial cells (Friedman 
1997) to set the stage for AMD development.
Blood flow analysis in patients with AMD shows 
decreased choroidal blood ﬂ  ow, velocity and volume in the 
fovea in AMD patients (Grunwald et al 2005). In addition, 
the severity of AMD increases in patients with the lowest 
circulatory parameters, possibly contributing to the ischemia 
and preceding the development of choroidal neovasculariza-
tion (Grunwald et al 2005). With the use of the laser Doppler 
ﬂ  owmetry, Metelitsina et al (2006) further investigated cho-
roidal blood ﬂ  ow in the fovea of patients with early AMD 
with or without systemic hypertension. AMD patients with 
systemic hypertension had 16.7% lower blood ﬂ  ow compared 
to patients without hypertension (Metelitsina et al 2006). 
These results further suggest that systemic hypertension may 
contribute to the progression of AMD and the development 
of choroidal neovascularization (Metelitsina et al 2006). Sato 
et al (2006) also used the laser Doppler ﬂ  owmetry to ﬁ  nd 
that the pulsatility index, pulsatility ratio and resistive index 
were higher in patients with AMD and increased with disease 
severity. They found no difference between the mean blood 
velocity and ﬂ  ow rates and no differences in arterial diameter, 
suggesting that patients with AMD suffer from decreased Clinical Interventions in Aging 2008:3(3) 479
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compliance in the arterial vasculature (Sato et al 2006). 
Pulsatile ocular blood ﬂ  ow has been found to be decreased in 
exudative AMD compared to nonexudative AMD or normal 
subjects (Mori et al 2001). Chen et al (2001) found that the 
pulsatile ocular blood ﬂ  ow in eyes with drusen was lower 
than in eyes with choroidal neovascularization and higher 
in eyes with disciform scar, implying that hemodynamic 
changes can be partly responsible for asymmetry in some 
AMD patients. Nevertheless, a recent study of Caucasian 
patients by Sandhu et al (2007) demonstrated no differences 
between the pulsatile ocular blood ﬂ  ow in asymmetric eyes of 
patients with AMD. Moreover, delayed choroidal ﬁ  lling time 
has been found in patients with dry AMD (Ciulla et al 2002). 
Prolonged choroidal ﬁ  lling phase was observed in 26% of 
eyes with early AMD using ﬂ  uorescein angiography and in 
32% of eyes using indocyanine green (Pauleikoff et al 1999). 
This prolonged ﬁ  lling was also associated with conﬂ  uent 
drusen and geographic atrophy in the fellow eye (Pauleikoff 
et al 1999). Presence of macular watershed zones was also 
correlated with AMD and one study found that choroidal 
neovascularization arose from the macular watershed zone 
in 91% of cases (Ross et al 1998).
Changes in the retrobulbar blood ﬂ  ow can provide a better 
understanding of the primary or secondary role of decreased 
blood ﬂ  ow in AMD. In an animal model, selective damage to 
retinal pigment epithelial cells caused degenerative changes 
to the choriocapillaris, suggesting that degeneration of cho-
riocapillaries in AMD can be secondary to dysfunction of 
the retinal pigment epithelial cells (Henkind and Gartner 
1983; Del Priore et al 1996). Therefore, secondary damage 
by retinal pigment epithelium is more likely to affect local 
blood vessels like the short posterior ciliary arteries and 
choriocapillaris than the ophthalmic or central retinal arteries. 
Changes in these vessels can support a more primary role of 
decrease in blood ﬂ  ow in the development of AMD, although 
a secondary autoregulatory response to a primary change 
elsewhere can not be ruled out (Ciulla et al 1999). Friedman 
et al (1995) reported that there is elevated pulsatility within 
all vessels including the ophthalmic, central retinal, and short 
posterior ciliary arteries, which can indicate an increase in the 
resistive index. Hosal et al (1998) reported that patients with 
AMD have lower blood velocity and higher resistive index 
in all retrobulbar vessels including the ophthalmic artery. 
Studies have found that blood ﬂ  ow velocity was lower in 
the ophthalmic artery and short posterior ciliary arteries of 
eyes with choroidal neovascularization compared with eyes 
without choroidal neovascularization (Uretmen et al 2003; 
Ciulla  et al 1999). Various studies have reported decreases 
in the velocity of the short posterior ciliary arteries in AMD 
patients (Friedman et al 1995; Dimitrova et al 2002). Ciulla 
et al (1999) also found a decrease in the end-diastolic velocity 
and an increase in the resistive index of the central retinal 
artery. There are a couple of hypotheses for this change in 
the central retinal artery blood ﬂ  ow velocity. First, reductions 
in central retinal artery blood ﬂ  ow may be due to global 
decreases in retrobulbar blood ﬂ  ow from the ophthalmic 
artery and its branches. Secondly, decreased retinal blood 
flow may be related to retinal angiomatous prolifera-
tion. Yannuzzi et al (2001) described retinal angiomatous 
proliferation as a phenomenon which occurs in a subgroup 
of neovascular AMD patients, where angiomatous prolif-
eration originates from the retina and extends posteriorly 
into the subretinal space, occasionally communicating with 
choroidal new vessels. Increased ﬂ  ow through new choroi-
dal vessels could decrease ﬂ  ow in the retina and the central 
retinal artery. Nevertheless, further studies are necessary to 
determine whether primary or secondary vascular changes 
play a role in AMD.
Although the hemodynamic abnormalities do not directly 
indicate that the vascular abnormalities precede the devel-
opment of AMD, they certainly suggest that hemodynamic 
changes play an important role in AMD pathogenesis. Fried-
man (1997, 2004) uses vascular theory to help explain what 
is known about the AMD pathophysiology. With advancing 
age, there is vascular stiffening and increased resistance. 
As overall vascular resistance increases, cerebral vascular 
resistance rises and leads to decreased choroidal perfusion 
and increased osmotic gradients against which retinal pig-
ment epithelial cells must pump. This leads to accumula-
tion of debris in the form of drusen. Furthermore, high 
choriocapillary pressure in the presence of calciﬁ  cation and 
fracture of Bruch’s membrane and ischemic damage to retinal 
pigment epithelial cells can cause the secretion of vascular 
growth factors leading to the development of choroidal 
neovascularization (Friedman 1997, 2004). Although this 
theory has not been confirmed and does not elucidate 
the differences between races, it provides a well-rounded 
description of vascular alterations and how they contribute 
to the pathogenesis of AMD.
Role of genetics in AMD
Numerous population-based studies have reported 
differences in prevalence and incidence of AMD between 
various ethnic/racial groups (Klein et al 1999, 2006; 
Mitchell et al 1995; Vingerling et al 1995b). Several 
studies have demonstrated an increased incidence of Clinical Interventions in Aging 2008:3(3) 480
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AMD within families to provide further support for the 
role of genetics in AMD (Seddon et al 1997; Klaver et al 
1998; Grizzard et al 2003). Therefore, it is important for 
investigators to continue to explore the role of genetics 
and environment on the development of AMD. Although 
genetic predisposition combined with environmental 
stressors seem to lead to disease development (Swaroop 
et al 2007), various studies have identiﬁ  ed chromosomal 
abnormalities associated with AMD. Some of the chro-
mosomal regions associated with AMD include 1q31–32, 
6q21 and 10q26 (Gold et al 2006; Swaroop et al 2007). 
Within chromosome segment 10q26, speciﬁ  c gene regions 
include PLEKHA1, LOC387715 and HTRA1 (Swaroop 
et al 2007). Complement factor H, within chromosomal 
segment 1q31–32, is a key regulator in the alternative com-
plement cascade and prevents uncontrolled complement 
activation (Yates et al 2007). Thakkinstian et al (2006) 
performed a meta-analysis between complement factor H 
Y402H polymorphism and AMD to ﬁ  nd that heterozygotes 
(TC) and homozygotes (CC) were, respectively, 2.5 and 6 
times more likely to have AMD than homozygote patients 
with the TT genotype. Nevertheless, a Japanese study 
found that this complement factor H gene did not appear 
to increase risk of AMD within their population (Gotoh 
et al 2006). This appears to demonstrate that there are 
differences amongst various ethnic groups. Furthermore, 
within chromosome 6q21, polymorphisms of complement 
factor B and complement component 2 have been shown 
to be a risk predictor of AMD (Gold et al 2006). These 
correlations between complement-related genes and AMD 
further support the role of the inﬂ  ammatory system in the 
development of AMD. In addition, a previous study by 
Mullins et al (2000) found that drusen can contain activated 
complement factors, acute phase reactants, coagulation 
proteins, immunoglobulins, and other proteins involved in 
the induction and activation of the immune response.
Not only can an individual’s genetic predisposition inﬂ  uence 
the development of AMD, but it is also associated with the rate 
of disease progression. Seddon et al (2007) analyzed patients 
from the Age-Related Eye Disease Study (AREDS) to determine 
whether variations within the complement factor H gene and the 
LOC387715 gene have prognostic importance in AMD disease 
progression. Although genetic polymorphisms in the comple-
ment factor H Y402H and LOC387715 A69S were associated 
with progression to more advanced AMD, the LOC387715 
genotype was also correlated with neovascular disease more 
than geographic atrophy. Patients who were homozygous for the 
risk alleles had a nearly 50% probability for AMD progression 
compared to the 5% risk in patients who are homozygous for 
the nonrisk alleles (Seddon et al 2007). Additionally, presence of 
the homozygous risk alleles combined with smoking and high 
body mass indices were associated with 19-fold increase 
of disease progression (Seddon et al 2007). Conversely, some 
genetic variations have been found to play a protective role 
in AMD development and progression. Apolipoprotein E is 
involved in transport and metabolism of lipid and cholesterol 
and in response to neural injury (Swaroop et al 2007). The ε4 
allele of apolipoprotein E has been associated with the reduced 
prevalence of AMD. There is strong evidence for the role of 
genetics in AMD, but further research is necessary to determine 
how genetic differences can ultimately lead to AMD.
Conclusion
Several systemic and ocular diseases increase in incidence 
and prevalence in the elderly population. Although AMD 
development shares many correlations with normal aging 
processes, other factors, such as genetic predisposition or 
environmental stressors, may account for disease develop-
ment (Figure 2). Furthermore, the similarities between drusen 
and atherosclerosis demonstrate that a vascular component 
may play a role in AMD development. Apart from the struc-
tural changes, age-related alterations in ocular hemodynamics 
can precede and correlate with the AMD pathogenesis, which 
further supports the vascular theory of AMD.
Although aging alone is not sufﬁ  cient to form AMD, it is 
apparent that the age-related changes and genetics are very 
important to the pathophysiology of AMD. Understanding the 
processes that develop with age and in age-related diseases 
can help guide new early treatment modalities. Further studies 
are warranted in order to learn how age-associated vascular 
and ocular structural changes lead to disease development. 
This will help generate the knowledge needed to identify 
target areas that may be useful to prevent disease progression 
through medical or surgical treatment.
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